Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21954067 | 0.89 | CYP19A1 (0.36) | LMNATSHRALDH1A1GAASORT1 | |
| SCHEMBL20845390 | 0.87 | FKBP1A (0.35) | LMNATSHRALDH1A1GAAPIK3CD | |
| SCHEMBL14589097 | 0.84 | CYP19A1 (0.39) | ALDH1A1GAAPIK3CDMEN1KMT2A | |
| SCHEMBL24594822 | 0.83 | LMNA (0.36) | LMNATSHRALDH1A1PIK3CDCYP19A1 | |
| SCHEMBL15199705 | 0.82 | ALDH1A1 (0.33) | LMNATSHRALDH1A1GAAMME | |
| SCHEMBL12194920 | 0.81 | PIK3CD (0.47) | ALDH1A1GAAPIK3CDMMECYP19A1 | |
| SCHEMBL24671656 | 0.81 | CYP19A1 (0.34) | LMNATSHRALDH1A1GAACYP19A1 | |
| SCHEMBL16566171 | 0.80 | CYP19A1 (0.44) | LMNAALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12410325 | 0.80 | CYP19A1 (0.41) | ALDH1A1GAAMEN1KMT2ACYP19A1 | |
| SCHEMBL22646532 | 0.80 | LMNA (0.41) | LMNATSHRALDH1A1GAASORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| WO-2021209007-A1 | ANTIBODY-DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | LMNA 1041/4885TSHR 1489/4885ALDH1A1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.